Product Images Sildenafil Citrate

This appears to be a table of recommended drug adjustments for various medications when taken with sildenafil (possibly for the treatment of pulmonary hypertension). The table lists various drugs and their impact on the “Atorvastatin-AUC,” “Azithromycin-AUC,” “Bosentan-AUC,” etc. For each drug, it indicates whether dose adjustments are necessary, recommended, or not necessary. The text also mentions a clinical study that indicates no benefit on exercise capacity when sildenafil is added to bosentan therapy.*

This is a description of a medication called Sildenafil Citrate 20mg tablet with a package size of 30. The medication has a lot number of 000000 and an expiration date of 3/31/2024. The source of the medication is NOC and the NOC number is 80434-0304-01. There is also an identification number of S e /N: 600000137919.*

This is a description of a medication called "Sildenafil Citrate 20mg Tablet." It comes in a pack of 60 and the product code is NOC 80425-0304-02 sourced from NOC 12668-0185-00. There is also a lot number 000000 with an expiry date of 8/31/2024. The first line of text is not readable and appears to be a scanning error.*

This is a label for a medication named "Sildenafil Citrate 20mg Tablet". The medication comes in a pack of 90 tablets, and the lot number is XXX, with an expiry date of 5/31/2024. It is likely an advanced medication used for treating certain medical conditions.*

This text provides a list of drugs and their 90% confidence interval (CI) for interacting drug fold change recommendations, including whether or not dose adjustment is recommended. There is also a graph displaying the change relative to interacting drug alone for Doxazosint at 25mg, 50mg, and 100mg Sildenafil. A note states that there is no benefit on exercise capacity when Sildenafil is added to Bosentan therapy. Another note is based on the effect of Ritonavir on Sildenafil PK.*

This is a table showing changes from the baseline (in meters) for a study conducted for 12 weeks. The study involved participants taking different doses of sildenafil, with one group receiving a placebo. The doses administered are 20mg, 40mg, and 80mg, taken three times a day. The table, however, does not provide any information or context regarding the objective, methods, or outcome of the study.*

This appears to be a medical document discussing the administration of sildenafil to patients with pulmonary arterial hypertension, and measuring its efficacy in a six-minute walk test. The document lists various patient characteristics such as age and gender, and includes data on their mean pulmonary artery pressure and six-minute walk distance. However, some of the text is truncated and incomplete, making it difficult to fully understand the context.*

The text provides a graph showing the percentage change in VOzpeu across different treatment groups with different doses. There were a total of 77 participants in the study. However, without additional context, it is difficult to understand what VOzpeu is and what the study aims to achieve.*

This is a table providing hazard ratios for overall survival in an Intent To Treat population who were given varying doses of Sildenafil. It shows the number of deaths, both on and off treatment, as well as the hazard ratio estimates from the proportional hazards model. The hazard ratios are stratified by actual previous PAH treatment and etiology of PAH.*

This is a table of hazard ratios for time to first event of clinical worsening in the intent-to-treat population for three different dosages of sildenafil. The table shows patient-years of follow-up, number of patients with clinical worsening, and the first event of clinical worsening. Hazard ratio estimates are given relative to sildenafil 5 mg and sildenafil 20 mg, along with confidence intervals and p-values. Note that sildenafil 5 mg is not an approved dosage. Clinical worsening events were defined as reduction from baseline in the 6-minute walk distance test by at least 15% and worsening functional class from baseline, both confirmed by a second test/evaluation within 2 weeks. The count of cases of disease progression, non-elective hospital stays for worsening PAH, and deaths are also provided as the first event of clinical worsening. The hazard ratio estimates are from the proportional hazards model, stratified by actual previous PAH treatment and etiology of PAH. The p-value is from the Wald test.*